has been cited by the following article(s):
[1]
|
PDL1 inhibitors may be associated with a lower risk of allograft rejection than PD1 and CTLA4 inhibitors: analysis of the WHO pharmacovigilance database
Frontiers in Immunology,
2025
DOI:10.3389/fimmu.2025.1514033
|
|
|